Company Overview
Company Type: Private Company
Website: www.liminalbiosciences.com
Number of Employees: 251
Year Founded: 1994
Total Amount Raised (CAD mm)†: 373.88
Total Rounds of Funding**:19
Latest Post-Money Valuation ($ mm) -
Latest Pre-Money Valuation ($ mm) -
† This number reflects the estimated value of the total new money raised through private placement rounds.
** This value is an estimate of the total number of funding rounds this company has received.


Business Description
Liminal BioSciences Inc., a development stage biopharmaceutical company, focuses on the development of novel small molecule drug therapeutics for inflammatory, fibrotic, and metabolic diseases in Canada and the United Kingdom. The company is developing LMNL6511, a selective antagonist for the G-protein coupled receptor 84, is expected to commence a Phase 1 clinical trial. It is also developing potential OXER1 antagonists and GPR40 agonists, which are in preclinical stage. The company was formerly known as Prometic Life Sciences Inc. and changed its name to Liminal BioSciences Inc. in October 2019. Liminal BioSciences Inc. was incorporated in 1994 and is headquartered in Laval, Canada. As of September 26, 2023, Liminal BioSciences Inc. was taken private.

Financial Information (Currency: CAD, in mm) 
Total Revenue
0.5
EBITDA
(31.5)
EBIT
(32.0)
Cash & ST Invst.
19.3
Net Income
1.3
Total Debt
1.2
Capital Expenditure
0.0
Total Assets
31.8
Total Debt/EBITDA
NM
U.S. Number of Employees 2023
-
U.S. Number of Employees 2022
-
U.S. Last Year Employee Growth %
-
Currency in CAD in mm, LTM as of Jun-30-2023 TEV and Market Cap are calculated using a close price as of Feb-02-2023


Estimates Snapshot (Current Fiscal Year End: Dec-31-2023)




Non-Periodic Estimates

Recommendation
Buy (1.00)


Key Professionals
Name
Title
Pritchard, Bruce 
Chief Executive Officer
Sartore, Patrick 
President
Rusaw, N. Nicole
Chief Financial Officer
Bridger, Gary J.
Interim Chief Scientific Officer & Non-Independent Director
Inamdar, Shrinal 
Manager of Investor Relations & Communications
Iskra, Marie 
Corporate Secretary & General Counsel
Burton, Steven J.
President of Prometic Bioseparations Ltd

Key Board Members
Name
Title
Krstajic, Aleksander 
Independent Chair of the Board
Bridger, Gary J.
Interim Chief Scientific Officer & Non-Independent Director
Best, Simon Geoffrey
Lead Independent Director
Klompas, Neil A.
Independent Director
Siklos, Eugene Sikloseugene
Non-Independent Director
Soffer, Benny 
Board Observer
Wach, Timothy Steven
Independent Director


Primary Industry Classification
Biotechnology


Primary Office Location
440 Armand-Frappier Boulevard Suite 300 | Laval, QC | H7V 4B4 | Canada
Phone: 450 781 0115   Fax: 450 781 4477

Current and Pending Investors
Investor
Initial Investment Date
Stake Type
Current Stake Amount
Round(s)
Thomvest Ventures, Inc.
Sep-11-2013
Majority
100.00 %
Debt

Prior Investors
Abraxis BioScience, Inc., Amorchem, AmorChem II, Armistice Capital LLC, Armistice Capital Master Fund Ltd., California Capital Equity, LLC, Celgene Corporation, Consonance Capital Management LP, Consonance Capital Master Account LP, Consonance Capital Opportunity Fund Management LP, Consonance Capital Partners, LP, Genesys Capital Partners Inc., P Consonance Opportunities Ltd, Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (SZSE:002399), Third Point LLC, Westech Investment Advisors, LLC


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
Fairhaven Pharmaceuticals Inc.
Fairhaven Pharmaceuticals Inc. a pharmaceutical company, which develops novel, small molecule, oral therapeutics for inflammatory conditions. Fairhaven Pharmaceuticals Inc. was formerly known as 9657754 CANADA INC. and changed its name to Fairhaven Pharmaceuticals Inc. in July 2018. The company was incorporated in 2018 and is based in Laval, Canada. Fairhaven Pharmaceuticals Inc. operates as a subsidiary of Liminal BioSciences Inc.

United States and Canada
Pharmaceuticals
-
-
-
Telesta Therapeutics Inc.
Telesta Therapeutics Inc., a biotechnology company, focuses on the licensing/acquisition and development of transformational therapeutics for the treatment of serious human diseases worldwide. It develops therapeutics in cancer, immune diseases, and targeted rare diseases. The company was formerly known as Bioniche Life Sciences Inc. and changed its name to Telesta Therapeutics Inc. in November 2014. Telesta Therapeutics Inc. was founded in 1979 and is headquartered in Montreal, Canada. As of October 31, 2016, Telesta Therapeutics Inc. operates as a subsidiary of ProMetic Life Sciences Inc.

United States and Canada
Biotechnology
10.00
38.00
1.00
Emergent BioSolutions, Inc., Plasma Collection Facility
As of August 10, 2015, Plasma Collection Facility of Emergent BioSolutions, Inc. was acquired by ProMetic Life Sciences Inc. Emergent BioSolutions, Inc. comprises a plasma collection facility. The facility is located in Canada.

United States and Canada
Biotechnology
-
-
-
Pathogen Removal and Diagnostic Technologies, Inc.
Pathogen Removal and Diagnostic Technologies, Inc. engages in the development of products and devices that remove and detect different pathogens from biological sources. The company was founded in 2002 and is based in Washington, District Of Columbia. As of October 5, 2009, Pathogen Removal and Diagnostic Technologies, Inc. operates as a subsidiary of ProMetic Life Sciences Inc.

United States and Canada
Biotechnology
-
-
-
7662114 Canada Inc.
7662114 Canada Inc. develops and manufactures plasma-derived therapeutic biosimilars. The company was founded in 2011 and is based in Laval, Canada. 7662114 Canada Inc. operates as a subsidiary of ProMetic Life Sciences Inc.

United States and Canada
Biotechnology
-
-
-
Arriva Pharmaceuticals, Inc.
Arriva Pharmaceuticals, Inc., a biopharmaceutical company, develops anti-inflammatory therapies for treating respiratory indications. The company focuses on various therapeutic areas of hereditary emphysema; and chronic obstructive pulmonary disease, including smoking-related emphysema, cystic fibrosis, and other respiratory indications. Its products include Respriva, which is formulated for inhalation delivery into the deep lung using nebulizers for the treatment hereditary emphysema; Ilomastat, an inhibitor of matrix metalloproteases; and Aeriva, a fusion protein that combines secretory leukocyte protease inhibitor and recombinant alpha 1-antitrypsin. The company was formerly known as AlphaOne Pharmaceuticals, Inc. and changed its name to Arriva Pharmaceuticals, Inc. in January 2001. The company was founded in 1997 and is headquartered in Alameda, California.

United States and Canada
Biotechnology
-
-
-
Arriva-ProMetic Inc.
Arriva-ProMetic Inc. operates as a joint venture between ProMetic Life Sciences Inc. and Arriva Pharmaceuticals, Inc.

United States and Canada
-
-
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Apr-05-2023
Sep-26-2023
Merger/Acquisition
Target
Liminal BioSciences Inc.
Thomvest Ventures, Inc. Buyer Funds:Structured Alpha LP
Genesys Capital Partners Inc.
11.09
Aug-10-2022
Aug-08-2022
Merger/Acquisition
Buyer
Pathogen Removal and Diagnostic Technologies, Inc.
Liminal BioSciences Inc.

0.00
Jan-27-2022
Cancelled
Merger/Acquisition
Seller
Manufacturing Site of Liminal BioSciences Inc
Ocugen, Inc. (NasdaqCM:OCGN)
Liminal BioSciences Inc.
-
Jun-23-2021
Oct-15-2021
Merger/Acquisition
Seller
Prometic Bioproduction Inc./Prometic Biotherapeutics Inc.
Kedrion S.p.A.
Liminal BioSciences Inc.
10.50
May-17-2021
May-21-2021
Merger/Acquisition
Seller
Prometic Plasma Resources Inc./Prometic Plasma Resources (USA) Inc.
Kedrion S.p.A.
Liminal BioSciences Inc.
17.00
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Oct-06-2023
Delistings
Liminal BioSciences Inc. Files Form 15
Sep-26-2023
Delistings
Liminal Biosciences' Shares No Longer To Be Listed on Nasdaq Capital Market
Sep-26-2023
Shelf Registration Filings
Liminal BioSciences Inc. has closed its Shelf Registration dated December 23, 2019 in the amount of $23.519066 million.
Sep-26-2023
Shelf Registration Filings
Liminal BioSciences Inc. has withdrawn its Shelf Registration dated December 01, 2020 in the amount of $200 million.
Sep-26-2023
Index Constituent Drops
Liminal BioSciences Inc.(NasdaqCM:LMNL) dropped from NASDAQ Composite Index

M&A Advisors
BMO Nesbitt Burns Inc., Cooley LLP, Lazard Middle Market LLC, Stikeman Elliott LLP


Advisors
Most Recent Auditor
PricewaterhouseCoopers LLP
M&A Advisors
BMO Nesbitt Burns Inc., Cooley LLP, Lazard Middle Market LLC, Stikeman Elliott LLP
Private Placement Advisors
Borden Ladner Gervais LLP, HealthPro BioVentures LLC, Piper Sandler Companies (NYSE:PIPR), Raymond James Ltd., Stifel, Nicolaus & Company, Incorporated, T.R. Winston & Company, LLC
Public Offering Advisors
BCF LLP, Borden Ladner Gervais LLP, Ernst & Young LLP (Canada), Raymond Chabot Grant Thornton (LLP)
Key development Advisor
Lazard Ltd (NYSE:LAZ)


Most Recent Auditor
PricewaterhouseCoopers LLP


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
GlobalData

Oct 06, 2023 01:35 AM
Liminal BioSciences Inc.
Liminal BioSciences Inc (LMNL.NASD) - Financial and Strategic SWOT Analysis Review
Reports
143
MarketLine

Sep 30, 2023 06:01 AM
Liminal BioSciences Inc.
ProMetic Life Sciences Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report
Reports
62
CFRA Equity Research

Sep 23, 2023 08:16 PM
Liminal BioSciences Inc.
Liminal BioSciences Inc.
Reports
9
GlobalData

Sep 20, 2023 05:06 AM
Liminal BioSciences Inc.
Liminal BioSciences Inc (LMNL.NASD) - Financial and Strategic SWOT Analysis Review
Reports
142
GlobalData

Sep 14, 2023 11:49 PM
Liminal BioSciences Inc.
Liminal BioSciences Inc (LMNL.NASD) - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
61
S&P Global Compustat

Sep 07, 2023 03:11 AM
Liminal BioSciences Inc.
Liminal BioSciences Inc 2023_09_07
Reports
15
ValuEngine, Inc.

Sep 01, 2023 03:00 AM
Liminal BioSciences Inc.
ValuEngine Rating and Forecast Report for LMNL
Reports
11
GlobalData

Aug 18, 2023 03:52 AM
Liminal BioSciences Inc.
Liminal BioSciences Inc (LMNL.NASD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
91
H.C. Wainwright & Co.
Pantginis, Joseph
Aug 07, 2023 03:55 AM
Liminal BioSciences Inc.
LMNL: Dropping Coverage
Reports
3
Pechala's Reports

Aug 04, 2023 11:00 PM
PJ2
LIMINAL BIOSCIENCES INC COMMON (LMNL=US) - SHORT AND LONG TERM FORECASTS FOR ACTIVE TRADERS
Reports
2


Ownership Summary

            Top Holders 
Holders by Type
Holder

Common Stock Equivalent Held

% of Total Shares Outstanding

Market Value (CAD in mm)

Position Date


Thomvest Ventures, Inc.

3,249,534

100.00

17.7

Sep-26-2023


Susquehanna International Group, LLP, Asset Management Arm

0

0.00

0.0

Jun-30-2023


Maxam Capital Management Ltd.

0

0.00

0.0

Oct-10-2023


Tanaka Capital Management Inc

0

0.00

0.0

Oct-10-2023


Morgan Stanley, Investment Banking and Brokerage Investments

0

0.00

0.0

Oct-10-2023


National Bank Investments Inc.

0

0.00

0.0

Oct-10-2023


Geode Capital Management, LLC

0

0.00

0.0

Aug-31-2023


Estabrook Capital Management, LLC

0

0.00

0.0

Oct-10-2023


Royal Bank of Canada, Banking & Securities Investments

0

0.00

0.0

Oct-10-2023


Best FRSE, OBE, Simon Geoffrey

0

0.00

0.0

Sep-26-2023



 



Top Buyers
Buyers
Common Stock Equivalent Held
Change
Thomvest Ventures, Inc.
3,249,534
1,261,921
Blackstone Alternative Investment Advisors LLC
0
40

Top Sellers
Sellers
Common Stock Equivalent Held
Change
Susquehanna International Group, LLP, Asset Management Arm
0
(14,133)
National Bank Investments Inc.
0
(9,852)
Maxam Capital Management Ltd.
0
(5,408)
Geode Capital Management, LLC
0
(3,391)
Best FRSE, OBE, Simon Geoffrey
0
(2,147)


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
Albumin (Future), Albupure, Alpha-1 Antitrypsin (Future), Aminophenyl Boronate Resins, C1 Esterase Inhibitors (Future), C1-INH (Future), Etoxiclear, Fabsorbent, Fezagepras, Fibrinogen (Future), Fluorinated Polymer Beads, GPR40, GPR84, GPR84 Antagonist (Future), Hromatography Column Hardware & Screening Kits, Hydrophobic Interaction Adsorbents, Insulin Adsorbents, Inter Alpha-One Inhibitor Proteins, Inter-Alpha Inhibitor Proteins (Future), Interalpha1 Inhibitor Protein (Future), Intravenous Immunoglobulin (Future), Ion-Exchange Resins, Isoclear, IVIG, LMNL6511, Mabsorbent, Mimetic Blue SA, Mimetic Ligand Adsorbents, Mimetic Ligand Purification Platform, OXER1 (Future), p-Aminobenzamidine Resins, P-Capt, PBI-0032 (Future), PBI-0110 (Future), PBI-1101 (Future), PBI-1308 (Future), PBI-1393, PBI-1522 (Future), PBI-1607 (Future), PBI-1737 (Future), PBI-4419 (Future), PBI-4494 (Future), PBI-4547 (Future), Peptide Ligands, Plasma Protein Purification System, PrioClear, Proprietary Plasma Purification Platform, Ryplazim (Future)


Upcoming Events
Date/Time
Type
Nov-10-2023
Estimated Earnings Release Date (S&P Global Derived)
* Future Events are subject to change.


Recent Major Filings

Key Filings
Filed On
Company Name
Source
Form Type
Size
Sep-26-2023
Liminal BioSciences Inc.
SEDAR
Change in Corporate Structure
260 KB
Sep-26-2023
Liminal BioSciences Inc.
SEDAR
Change in Corporate Structure
260 KB
Sep-26-2023
Liminal BioSciences Inc.
SEDAR
Change in Corporate Structure
260 KB
Sep-26-2023
Liminal BioSciences Inc.
SEDAR
Material Change Report
271 KB
Sep-26-2023
Liminal BioSciences Inc.
SEDAR
Material Change Report
271 KB
Sep-26-2023
Liminal BioSciences Inc.
SEDAR
Material Change Report
271 KB
Sep-26-2023
Liminal BioSciences Inc.
SEDAR
Documents Affecting the Rights of Security Holders
608 KB
Sep-26-2023
Liminal BioSciences Inc.
SEDAR
Documents Affecting the Rights of Security Holders
608 KB
Sep-26-2023
Liminal BioSciences Inc.
SEDAR
Documents Affecting the Rights of Security Holders
608 KB
Sep-26-2023
Liminal BioSciences Inc.
SEDAR
News Releases
34 KB


Insider Trades
Holder Name
Trade Date Range
Security Type
Transacted Shares
Transaction Value Range (CAD)
Transaction Type
% Change
Source
Thomvest Ventures, Inc.
Sep-26-2023
Common Shares
1,261,921
14,589,201
Open Market Acquisition
63.49
Multiple
Thomvest Ventures, Inc.
Sep-26-2023
Common Shares
1,261,921
14,589,201
Open Market Acquisition
63.49
Multiple
Best FRSE, OBE, Simon Geoffrey (Lead Independent Director)
Sep-26-2023
Common Shares
(2,147)
(24,822)
Open Market Disposition
(100.00)
Multiple
-
Sep-26-2023
Common Shares
(630)
(7,284)
Open Market Disposition
-
Exchange Announcement
-
Sep-26-2023
Common Shares
(1,517)
(17,538)
Open Market Disposition
-
Exchange Announcement
Pritchard BA, CA, FIOD, Bruce  (Chief Executive Officer)
Sep-26-2023
Common Shares
(1,346)
(15,561)
Open Market Disposition
(100.00)
Multiple
-
Sep-26-2023
Common Shares
(379)
(4,382)
Open Market Disposition
-
Exchange Announcement
-
Sep-26-2023
Common Shares
(967)
(11,180)
Open Market Disposition
-
Exchange Announcement
Sartore, Patrick  (President)
Sep-26-2023
Common Shares
(317)
(3,665)
Open Market Disposition
(100.00)
Multiple
-
Sep-26-2023
Common Shares
(162)
(1,873)
Open Market Disposition
-
Exchange Announcement
-
Sep-26-2023
Common Shares
(76)
(879)
Open Market Disposition
-
Exchange Announcement
-
Sep-26-2023
Common Shares
(79)
(913)
Open Market Disposition
-
Exchange Announcement
Excluding Automatic Transactions
Key Board Members Details
Name
Title
Phone
Fax
Email
Krstajic, Aleksander 
Independent Chair of the Board
450 781 0115
450 781 4477

Bridger, Gary J.
Interim Chief Scientific Officer & Non-Independent Director
450 781 0115
450 781 4477

Best, Simon Geoffrey
Lead Independent Director
(450) 781-0115
450 781 4477
s.best@prometic.com
Klompas, Neil A.
Independent Director
450 781 0115
450 781 4477

Siklos, Eugene Sikloseugene
Non-Independent Director
450 781 0115
450 781 4477

Soffer, Benny 
Board Observer
450 781 0115
450 781 4477

Wach, Timothy Steven
Independent Director
450 781 0115
450 781 4477

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Pritchard, Bruce 
Chief Executive Officer
450.781.0115
450 781 4477
b.pritchard@liminalbiosciences.com
Sartore, Patrick 
President
450-781-0115
450-781-4477
p.sartore@liminalbiosciences.com
Rusaw, N. Nicole
Chief Financial Officer
450 781 0115
450 781 4477
nrusaw@transitiontherapeutics.com
Bridger, Gary J.
Interim Chief Scientific Officer & Non-Independent Director
450 781 0115
450 781 4477

Inamdar, Shrinal 
Manager of Investor Relations & Communications
(450) 781-0115
450 781 4477
s.inamdar@liminalbiosciences.com
Iskra, Marie 
Corporate Secretary & General Counsel
450-781-0115
450-781-4457
m.iskra@prometic.com
Burton, Steven J.
President of Prometic Bioseparations Ltd
450 781 0115
450 781 4477

* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 
